Company intelligence / Profile preview

Combotope Therapeutics

Kongens Lyngby, Denmarkcombotopetherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing tumor-specific antibodies targeting aberrantly glycosylated proteins found exclusively on cancer cells. Currently in research collaboration with CiMaas for CAR-NK development targeting Mucin-1 tumor glycoform.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Bispecific antibodies (BsAb)Bispecific T-cell engagers (BiTE)Radioimmune mAbs (RI-mAbs)CAR-NK cellsCAR-T cells
Industry: Biotech

Partnerships

CiMaas (oncology research and license option agreement)

Beyond the preview

Go deeper on Combotope Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Combotope Therapeutics.

Explore the full profile